- Home
- MCRB
as 01-21-2025 4:00pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 131.0M | IPO Year: | 2015 |
| Target Price: | $5.63 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $1.53 | Next Earning Date: | 03-04-2025 |
| Revenue: | $126,325,000 | Revenue Growth: | 12856.41% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 735 | $397.64 | 90,404 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Nov 15 '24 | Sell | $0.54 | 878 | $474.73 | 135,192 | |
| von Moltke Lisa | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 977 | $528.26 | 32,415 | |
| Shaff Eric D. | MCRB | CEO and President | Nov 15 '24 | Sell | $0.54 | 2,505 | $1,354.95 | 170,389 | |
| Henn Matthew R. | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 927 | $501.23 | 77,770 | |
| Young Teresa L. | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 2,983 | $2,058.57 | 90,404 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Oct 27 '24 | Sell | $0.69 | 4,259 | $2,939.14 | 135,192 | |
| von Moltke Lisa | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 4,334 | $2,991.33 | 32,415 | |
| Shaff Eric D. | MCRB | CEO and President | Oct 27 '24 | Sell | $0.69 | 8,748 | $6,036.99 | 170,389 | |
| Henn Matthew R. | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 3,984 | $2,749.36 | 77,770 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Seres Therapeutics Receives First of 2 Installments Related to VOWST Sale
GlobeNewswire
6 days ago
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
TipRanks
12 days ago
Seres announces new translational biomarker results from SER-155 Phase 1b study
MT Newswires
13 days ago
Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended
GlobeNewswire
13 days ago
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Simply Wall St.
a month ago
The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable
TipRanks
a month ago
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference
GlobeNewswire
a month ago
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.